You are here

Alnylam

MedCo Touts New Data for Long-Lasting Heart Drug as Reckoning Looms

MedCo Touts New Data for Long-Lasting Heart Drug as Reckoning Looms

Xconomy

The Medicines Company

Flag link:

Can Pfizer Leap Over the Competition With This Potential Blockbuster?

Can Pfizer Leap Over the Competition With This Potential Blockbuster?

Motley Fool

Akcea Therapeutics

Eidos Therapeutics

Flag link:

FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea

FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea

Xconomy

Flag link:

Vendu! Weeks after Sanofi cuts ties to Alnylam, the pharma giant offloads $842M of its stock

Vendu! Weeks after Sanofi cuts ties to Alnylam, the pharma giant offloads $842M of its stock

Endpoints

Flag link:

Alnylam posts strong Onpattro sales as competition heats up

Alnylam posts strong Onpattro sales as competition heats up

Biopharma Dive

Flag link:

Bio Roundup: Nationwide’s Rise, a Surgeon’s Quest, CRISPR USA & More

Bio Roundup: Nationwide’s Rise, a Surgeon’s Quest, CRISPR USA & More

Xconomy

Adverum Biotechnologies

Blackstone Life Sciences

Flag link:

Alnylam's givosiran reduces mean porphyria attacks by 74% in Phase III

Alnylam's givosiran reduces mean porphyria attacks by 74% in Phase III

BioCentury

acute hepatic porphyria

Flag link:

Regeneron, Alnylam spell out a research alliance that could run beyond a decade, with billions built in for success

Regeneron, Alnylam spell out a research alliance that could run beyond a decade, with billions built in for success

Endpoints

Flag link:

Alnylam Gets $800M From Regeneron to Bring RNAi to Eye, Brain Diseases

Alnylam Gets $800M From Regeneron to Bring RNAi to Eye, Brain Diseases

Xconomy

Flag link:

2 Biotechs With Big Dates in April

2 Biotechs With Big Dates in April

Motley Fool

Intercept Pharmaceuticals

Flag link:

After landing a historic FDA OK, Alnylam chief John Maraganore scores a big raise

After landing a historic FDA OK, Alnylam chief John Maraganore scores a big raise

Endpoints

John Maraganore

Flag link:

Data in Hand, Alnylam To Seek OK For Second RNAi Drug

Data in Hand, Alnylam To Seek OK For Second RNAi Drug

Xconomy

acute hepatic porphyria

Flag link:

Upcoming events – Fibrogen and Alnylam look to broaden their horizons

Upcoming events – Fibrogen and Alnylam look to broaden their horizons

EP Vantage

Duchenne Muscular Dystrophy

Flag link:

Alnylam Pharmaceuticals Is Launched and Ready for More

Alnylam Pharmaceuticals Is Launched and Ready for More

Motley Fool

ATTR amyloidosis

Flag link:

Is the Smoldering NASH Market Ready to Burst Into Flames?

Is the Smoldering NASH Market Ready to Burst Into Flames?

BioSpace

Gilead Sciences

Bristol-Myers Squibb

Intercept Pharmaceuticals

Flag link:

Alnylam CEO talks politics, gene therapy and not becoming Pfizer

Alnylam CEO talks politics, gene therapy and not becoming Pfizer

BioPharma Dive

John Maraganore

Flag link:

5 Top Drug/Biotech Merger & Acquisition Targets for 2019

5 Top Drug/Biotech Merger & Acquisition Targets for 2019

Yahoo/Zacks.com

Vertex Pharmaceuticals

Flag link:

Alnylam's Onpattro sales look 'disappointing' in early days of RNAi launch: analyst

Alnylam's Onpattro sales look 'disappointing' in early days of RNAi launch: analyst

Fierce Pharma

hATTR amyloidosis

Flag link:

Alnylam shares drop 1.8% on new FDA approval strategy for rare disease drug

Alnylam shares drop 1.8% on new FDA approval strategy for rare disease drug

Marketwatch

acute hepatic porphyria

Flag link:

FDA clears rare disease therapy from Akcea, Ionis

FDA clears rare disease therapy from Akcea, Ionis

Biopharma Dive

Ionis Pharmaceuticals

hATTR amyloidosis

Flag link:

Pages